Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ying Cheng, MD"'
Autor:
Jie Wang, MD, PhD, Yi-Long Wu, MD, Shun Lu, MD, PhD, Qun Wang, MD, Shanqing Li, MD, Wen-Zhao Zhong, MD, PhD, Qiming Wang, MD, Wei Li, MD, PhD, Buhai Wang, MD, Jun Chen, MD, Ying Cheng, MD, Hongbing Duan, MD, Gaofeng Li, MD, Li Shan, MD, Yangbo Liu, MS, Jing Liu, MD, Xiangning Huang, PhD, Ana Bolanos, MD, Jie He, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100621- (2024)
Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improveme
Externí odkaz:
https://doaj.org/article/a94bd03454c54595bceebab2019eeee9
Autor:
Shun Lu, MD, Jian Fang, MD, Xingya Li, MD, Lejie Cao, MD, Jianying Zhou, MD, Qisen Guo, MD, Zongan Liang, MD, Ying Cheng, MD, Liyan Jiang, MD, Nong Yang, MD, Zhigang Han, MD, Jianhua Shi, MD, Yuan Chen, MD, Hua Xu, MD, Helong Zhang, MD, Gongyan Chen, MD, Rui Ma, MD, Sanyuan Sun, MD, Yun Fan, MD, Songhua Fan, MD, Jie Yu, MD, Puhan Lu, PhD, Xian Luo, MS, Weiguo Su, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100407- (2022)
Introduction: Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon 14 skipping alterations (MET ex14 positive) at the
Externí odkaz:
https://doaj.org/article/a7ca95375de14255b657fbafab37ec69
Autor:
Xue-Ning Yang, MD, Hong-Hong Yan, MSc, Jun Wang, MD, Xiang-Yang Chu, MD, Zhi-Dong Liu, MD, Yi Shen, MD, Hai-Tao Ma, MD, Xiang-Ning Fu, MD, Jian Hu, MD, Nai-Kang Zhou, MD, Yong-Yu Liu, MD, Xin-Ming Zhou, MD, Jing-Song Li, MD, Kang Yang, MD, Jian Li, MD, Lin Xu, MD, Si-Yu Wang, MD, Qun Wang, MD, Lun-Xu Liu, MD, Shun Xu, MD, Zhong-Yuan Chen, MD, Hong-He Lou, MD, Chang-Li Wang, MD, Ying Cheng, MD, Si-Yang Liu, MD, Xu-Chao Zhang, MD, Wen-Zhao Zhong, MD, Yi-Long Wu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100257- (2022)
Introduction: The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD) remains unstandardized. We analyzed the survival outcomes of these patients based on EGFR mutation status and adjuvant chemotherapy treatment. Methods: This non
Externí odkaz:
https://doaj.org/article/8b930ddc7d7d44b482cd2a689f7ea99e
Autor:
Ying Cheng, MD, Li Zhang, MD, Jie Hu, MD, PhD, FCCP, Donglin Wang, MD, ChengPing Hu, MD, Jianying Zhou, MD, Lin Wu, MD, Lejie Cao, MD, Jiwei Liu, MD, Helong Zhang, MD, Hong Sun, MD, Ziping Wang, PhD, Hongjun Gao, MD, Yuping Sun, MD, Ben Li, PhD, Xiaohan Hu, PhD, MPH, Paul Schwarzenberger, MD, Luis Paz-Ares, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 10, Pp 100225- (2021)
Introduction: Pembrolizumab plus chemotherapy significantly improved survival outcomes versus placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC in the randomized, double-blind, phase 3 KEYNOTE-407 study. We pre
Externí odkaz:
https://doaj.org/article/4bbc1ceac0d24389ad9fdf01f2ce0f2a
Autor:
Jinjie He MD, Yue Liu PhD, Chengcheng Liu PhD, Hanguang Hu PhD, Lifeng Sun MD, Dong Xu MD, Jun Li MD, Junye Wang MD, Xiaobing Chen MD, Rongbo Lin MD, Yi Jiang MD, Yanqiao Zhang MD, Weisheng Zhang MD, Ying Cheng MD, Xiaohong Wu MD, Mingzhi Fang MD, Enxiao Li MD, Ye Xu MD, Ye Chen MD, Jiayi Li MD, Yanyan Cui MD, Zhanyu Pan MD, Songnan Zhang MD, Ying Yuan PhD, Kefeng Ding PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Background: Chemotherapy combined with antivascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor monoclonal antibodies is the most promising approach to prolong survival and improve the quality of life of patients with un
Externí odkaz:
https://doaj.org/article/ea3bcbdb33614543aaa810bf80794bbf